Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts

Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Metabolomics Consortium

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease (AD) is the most common cause of dementia. The mechanism of disease development and progression is not well understood, but increasing evidence suggests multifactorial etiology, with a number of genetic, environmental, and aging-related factors. There is a growing body of evidence that metabolic defects may contribute to this complex disease. To interrogate the relationship between system level metabolites and disease susceptibility and progression, the AD Metabolomics Consortium (ADMC) in partnership with AD Neuroimaging Initiative (ADNI) is creating a comprehensive biochemical database for patients in the ADNI1 cohort. We used the Biocrates Bile Acids platform to evaluate the association of metabolic levels with disease risk and progression. We detail the quantitative metabolomics data generated on the baseline samples from ADNI1 and ADNIGO/2 (370 cognitively normal, 887 mild cognitive impairment, and 305 AD). Similar to our previous reports on ADNI1, we present the tools for data quality control and initial analysis. This data descriptor represents the third in a series of comprehensive metabolomics datasets from the ADMC on the ADNI.

Original languageEnglish (US)
Number of pages1
JournalScientific Data
Volume6
Issue number1
DOIs
StatePublished - Oct 17 2019

    Fingerprint

ASJC Scopus subject areas

  • Statistics and Probability
  • Information Systems
  • Education
  • Computer Science Applications
  • Statistics, Probability and Uncertainty
  • Library and Information Sciences

Cite this

Alzheimer’s Disease Neuroimaging Initiative, & Alzheimer’s Disease Metabolomics Consortium (2019). Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts. Scientific Data, 6(1). https://doi.org/10.1038/s41597-019-0181-8